Aktiebolaget Hassle v Alphapharm Pty Ltd [1999] FCA 1394

Aktiebolaget Hassle v Alphapharm Pty Ltd [1999] FCA 1394

Assuming validity of the patent, the Alphapharm product would take the essential integers of claims 1, 4, 10, 11, 12, 13, 14, 15 and, on the additional assumption that claims 16 and 17 are not invalid as methods of treating the human body, claims 16 and 17. The core of the Alphapharm product includes the sugar seed coated with the omeprazole-containing mixture, the core includes an alkaline reacting compound because a substance in it produces the required micro-pH, the sub-coat is inert reacting, the relevant pellets had water content below 1.5 per cent by weight, and the sub-coat was not less than two microns thick. The evidence did not establish infringement of claims 5 or 6 because the...

Jurisdiction
Australia
Judgment Date
12 October 1999
Procedural Posture
Intellectual Property; Patents; Pharmaceutical Formulation Infringement Proceeding / Reasons for Judgment on Infringement Issues, Assuming Validity of the Patent
Outcome
Assuming validity, Alphapharm's threatened conduct would infringe claims 1, 4, 10, 11, 12, 13, 14, 15 and, subject to an additional validity assumption, claims 16 and 17; the Court was not prepared to find infringement of claims 5 or 6.
Legal Topics
['pharmaceutical Formulation' 'patent Infringement' 'combination Patent' 'mechanical Equivalents' 'omeprazole Enteric Coated Preparation']
['intellectual Property' 'patents'] ['pharmaceutical Formulation' 'patent Infringement' 'combination Patent' 'mechanical Equivalents' 'omeprazole Enteric Coated Preparation']

Case Brief

Summary, issues, holding and outcome

More case intelligence is available

Unlock the full research layer for this judgment.

Full judgment text Downloadable case file Legal principles 1 Authorities cited 2 Party arguments 2 Amounts and remedies 1
Sign in to unlock

Procedural Posture

Intellectual Property; Patents; Pharmaceutical Formulation Infringement Proceeding / Reasons for Judgment on Infringement Issues, Assuming Validity of the Patent

Legal Issues

  1. 1 ['Whether, assuming the patent to be valid, the Alphapharm product or the process by which it is prepared would infringe one or more claims of the patent.' 'What is the core or core material of the Alphapharm product.' 'Whether the core of the Alphapharm product contains an alkaline reacting compound.' 'Whether the second coating layer of the Alphapharm product is inert reacting.' 'Whether the core of the Alphapharm product includes a pH-buffering alkaline compound for the purposes of claims 5 and 6.' 'Whether the water content of the final dosage form of the Alphapharm product does not exceed 1.5 per cent by weight for claim 10.' 'Whether the sub-coating layer of the Alphapharm product is not less than two microns thick for claim 11.']

Ratio Decidendi

Assuming validity of the patent, the Alphapharm product would take the essential integers of claims 1, 4, 10, 11, 12, 13, 14, 15 and, on the additional assumption that claims 16 and 17 are not invalid as methods of treating the human body, claims 16 and 17. The core of the Alphapharm product includes the sugar seed coated with the omeprazole-containing mixture, the core includes an alkaline reacting compound because a substance in it produces the required micro-pH, the sub-coat is inert reacting, the relevant pellets had water content below 1.5 per cent by weight, and the sub-coat was not less than two microns thick. The evidence did not establish infringement of claims 5 or 6 because the...

Court Disposition

Assuming validity, Alphapharm's threatened conduct would infringe claims 1, 4, 10, 11, 12, 13, 14, 15 and, subject to an additional validity assumption, claims 16 and 17; the Court was not prepared to find infringement of claims 5 or 6.

Orders

  • []